Incyte Corporation
INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor tā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$99.13
Price-1.19%
-$1.19
1Y
Price
Market Cap
$19.804b
Large
Price/Earnings 3y Avg5y Avg
14x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+28.9%
EBITDA Margin+23.8%
Net Profit Margin+28.2%
Free Cash Flow Margin+28.9%
EBITDA Margin+23.8%
Net Profit Margin+28.2%
Free Cash Flow MarginRevenue
$5.361b
+4.3%
1y CAGR+13.4%
3y CAGR+12.3%
5y CAGREarnings
$1.432b
+11.3%
1y CAGR+1253.9%
3y CAGR+959.3%
5y CAGREPS
$7.08
+10.5%
1y CAGR+1363.2%
3y CAGR+1041.0%
5y CAGRBook Value
$5.552b
$7.339b
Assets$1.787b
Liabilities$33.827m
DebtDebt to Assets
0.5%
-
Debt to EBITDAFree Cash Flow
$1.451b
+7.1%
1y CAGR+135.5%
3y CAGR+89.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company